Last reviewed · How we verify
NCT05737602
Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease
NA trial testing 3RP-VHL in Von Hippel-Lindau Disease in 40 participants. Enrolling by invitation.
1 May 2026
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 40 |
| Start date | 30 July 2024 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 July 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 3RP-VHL
Conditions studied
- Von Hippel-Lindau Disease — all drugs for Von Hippel-Lindau Disease →
- Genetic Disorder — all drugs for Genetic Disorder →
Sponsor
Massachusetts General Hospital
Who can join
18 and older, any sex, with Von Hippel-Lindau Disease or Genetic Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Relaxation Response Resiliency Program (3RP) has shown efficacy in improving coping and resilience across diverse populations; however, little is known about how it helps individuals manage the challenges of living with a chronic illness. This study proposes to pilot test an adapted version of the 3RP among patients living with VHL.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05737602
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Von Hippel-Lindau Disease
Currently open trials in the same condition.
- NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
- NCT06194669 — Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells · recruiting
- NCT05424016 — Propranolol and Von Hippel-Lindau Disease · NA · recruiting
- NCT06523582 — Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients · recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05737602 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 29 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05737602.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing